RTX-240 for the Treatment of Advanced Solid Tumors
Study Title
Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors
Status
Enrolling
Primary Objectives
Safety Assessment
Pharmacodynamics of RTX-240 will be evaluated through changes in natural killer and T cell numbers relative to baseline
Anti-Tumor activity of RTX-240 measured by Overall Response Rate, or ORR
If you are a patient or a loved one interested in learning more about RTX-240 for the treatment of cancer or participating in a clinical trial, please visit www.rubiustrials.com.